Xponance Inc. Cuts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Xponance Inc. trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 7.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,728 shares of the biotechnology company’s stock after selling 882 shares during the period. Xponance Inc.’s holdings in Sarepta Therapeutics were worth $1,131,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. DMC Group LLC lifted its holdings in shares of Sarepta Therapeutics by 2.9% during the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after buying an additional 93 shares during the period. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 154 shares during the period. Natixis Advisors L.P. lifted its holdings in shares of Sarepta Therapeutics by 0.6% during the 3rd quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company’s stock valued at $3,155,000 after buying an additional 160 shares during the period. LGL Partners LLC lifted its holdings in shares of Sarepta Therapeutics by 4.6% during the 3rd quarter. LGL Partners LLC now owns 4,196 shares of the biotechnology company’s stock valued at $509,000 after buying an additional 186 shares during the period. Finally, Harbor Capital Advisors Inc. lifted its holdings in shares of Sarepta Therapeutics by 6.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 3,244 shares of the biotechnology company’s stock valued at $393,000 after buying an additional 196 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Citigroup increased their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, February 29th. UBS Group raised their target price on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Evercore ISI raised their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a report on Tuesday, February 20th. Barclays raised their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $158.38.

Insider Activity

In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the transaction, the chief financial officer now owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $123.25, for a total value of $1,848,750.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,815,030. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the transaction, the chief financial officer now owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 over the last 90 days. Corporate insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Trading Up 6.1 %

Shares of Sarepta Therapeutics stock opened at $124.25 on Thursday. The firm has a market cap of $11.67 billion, a price-to-earnings ratio of -20.30 and a beta of 0.94. The business has a 50-day moving average price of $126.18 and a 200-day moving average price of $110.31. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The firm had revenue of $396.80 million during the quarter, compared to analyst estimates of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.24) earnings per share. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.